Nuvalent, Inc. (NUVL)
| Previous close | 65.48 |
| Open | 66.38 |
| Bid | 65.29 x 100 |
| Ask | 65.82 x 100 |
| Day's range | 65.16 - 67.09 |
| 52-week range | 37.95 - 89.39 |
| Volume | |
| Avg. volume | 481,081 |
| Market cap | 4.23B |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 101.25 |
PR NewswireNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported first quarter 2024 financial results.
ZacksWhy Earnings Season Could Be Great for Nuvalent (NUVL)
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- PR Newswire
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520). The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego. The posters wi
